Related Experiment Videos

Amikacin therapy for serious gram-negative infection

JAMA
|February 7, 1977
PubMed

Insights

Amikacin sulfate effectively treated severe Gram-negative infections, including those resistant to gentamicin. This antibiotic demonstrated high cure rates with manageable side effects in patients with serious bacterial infections.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Severe Gram-negative bacterial infections pose significant treatment challenges, especially when resistant to conventional antibiotics.
  • Gentamicin resistance in Gram-negative bacilli necessitates alternative therapeutic options.
  • Amikacin sulfate is an aminoglycoside antibiotic with broad-spectrum activity.

Purpose of the Study:

  • To evaluate the efficacy and safety of amikacin sulfate in treating severe Gram-negative infections.
  • To assess drug levels in various body fluids.
  • To identify adverse effects associated with amikacin sulfate treatment.

Main Methods:

  • A prospective study involving 18 patients with 19 severe infections.
  • Amikacin sulfate administered at a dose of 15 mg/kg/day.
  • Monitoring of bacteriologic cure, serum, bile, and pleural fluid drug levels, and adverse events.

Main Results:

  • Bacteriologic cure was achieved in 18 out of 19 infections (94.7%).
  • Effective drug concentrations were demonstrated in serum, bile, and pleural fluid.
  • Adverse events included drug-related fever (1 patient), rash with monilial intertrigo (1 patient), and reversible renal toxicity (3 patients). No ototoxicity was observed.

Conclusions:

  • Amikacin sulfate is an effective antibiotic for treating severe Gram-negative infections, particularly those caused by gentamicin-resistant organisms.
  • The drug is well-tolerated, with manageable and reversible side effects.
  • Therapeutic drug monitoring confirmed adequate drug levels in key body fluids.

Related Concept Videos